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Abstract
Background: Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease
(ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with
clinical and cerebrospinal fluid (CSF) markers in ADAD. We also evaluate serum NfL differences between clinical groups.
Methods: Serum NfL was measured cross-sectionally in 60 individuals from ADAD families using an ultrasensitive
immunoassay on the Single molecule array (Simoa) platform and longitudinally in an exploratory study in a subset of
six mutation carriers. Spearman coefficients assessed associations between serum NfL and relevant measures.
Differences between groups were evaluated by Kruskal-Wallis and Mann-Whitney U tests.
Results: Forty-two participants were mutation carriers: 22 symptomatic (SMC) and 20 asymptomatic (AMC).
Eighteen subjects were non-carriers and cognitively normal (controls (CTR)). Serum NfL correlated with the
estimated years from symptoms onset across mutation carriers (rho = 0.75, p < 0.001). In mutation carriers,
serum NfL also showed strong correlation with clinical (rho = 0.70, p < 0.001) and cognitive (rho = −0.77, p < 0.001)
measures and CSF NfL, total tau and phosphorylated tau levels (rho = 0.72, 0.71, and 0.71, respectively, all p < 0.001).
Serum NfL concentration was higher in SMC than in AMC and CTR.
Conclusions: Serum NfL might be a feasible non-invasive biomarker to track disease onset and severity in ADAD.
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Background
Autosomal dominant Alzheimer’s disease (ADAD), with
its almost 100% penetrance and relatively predictable
age of onset, allows the evaluation of disease-modifying
treatments at early or pre-symptomatic stages of the dis-
ease [1]. Two trials, the Dominantly Inherited Alzheimer
Network Trials Unit and the Alzheimer’s Prevention Ini-
tiative [2, 3], are already ongoing. Thus, there is consid-
erable interest in finding non-invasive biomarkers that
could track the disease progression or provide evidence
of disease modification. Cerebrospinal fluid (CSF) bio-
markers have shown strong correlations with clinical
and cognitive measures in ADAD [4, 5]. However, re-
peated CSF sampling is not always feasible or well toler-
ated. Blood-based biomarkers are less invasive and allow
more frequent determinations, although they are chal-
lenging due to the lower concentration of brain analytes.
Recently, measurement of neurofilament light (NfL)
concentration using an ultrasensitive immunoassay on
the Single molecule array (Simoa) platform has been
demonstrated to be feasible and reliable, both in spor-
adic Alzheimer’s disease (AD) [6] and ADAD [7], as well
as in other neurodegenerative or neuroinflammatory dis-
eases such as frontotemporal dementia [8], progressive
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supranuclear palsy [9], Huntington’s disease [10], and
multiple sclerosis [11].
In this study, we analysed serum NfL levels in a Span-
ish cohort of ADAD individuals and investigated
whether they were associated with clinical markers of
disease severity and CSF biomarkers.
Methods
Participants
We studied 60 participants from ADAD families caused
by 16 different mutations (with number of subjects, both
carriers and non-carriers, indicated in brackets): the
T116I (n = 1), H131R (n = 3), M139 T (n = 7), H163R (n
= 2), S169P (n = 6), L173F (n = 4), G206D (n = 2), G209E
(n = 1), R220G (n = 3), L235R (n = 3), K239 N (n = 8),
L282R (n = 6), L286P (n = 8), G378R (n = 2), and I439S
(n = 2) mutations in the PSEN1 gene and the I716T (n =
2) mutation in the APP gene. All the participants were
recruited from the genetic counselling programme for
familial dementias (PICOGEN) at the Hospital Clinic,
Barcelona, Spain [12]. The study was approved by the
Hospital Clinic ethics committee and all subjects gave
written informed consent.
All participants underwent a complete clinical evalu-
ation, and a comprehensive neuropsychological battery
was administered to 52 subjects [12]. Subjects were classi-
fied as asymptomatic if they had no cognitive complaints,
their cognitive performance was normal, and they scored
0 on the Clinical Dementia Rating (CDR) scale. They were
classified as symptomatic if their CDR score was > 0 or if
their cognitive performance was ≥ 1.5 standard deviations
(SDs) below the mean. We calculated the estimated years
from symptom onset (EYO) for asymptomatic mutation
carriers (AMC) as the subject’s age at the time of the study
minus their parental age at onset. The parental age at on-
set was determined by a semi-structured interview in
which family members were asked about the age of first
progressive cognitive decline in the affected parent similar
to the Dominant Inherited Alzheimer’s Network [13].
Non-carriers were used as the control population (CTR).
Measurement of serum NfL concentrations
The serum NfL concentration was measured using an
ultrasensitive immunoassay on the Simoa platform in
the DRI Fluid Biomarker Laboratory at UCL London,
UK, using the commercially available NF-Light kit ac-
cording to the manufacturer’s instructions (Quanterix,
Lexington, MA). All measurements were performed by
specially trained personnel in one round of experiments
using one batch of reagents.
Measurement of CSF biomarkers
CSF samples were available from 35 participants.
Commercially available single-analyte enzyme-linked
immunosorbent assay (ELISA) kits were used to de-
termine levels of CSF Aβ1–42, total tau, phosphory-
lated tau (INNOTEST, Fujirebio-Europe), and NfL
(UmanDiagnostics) at the Alzheimer’s Disease and
Other Cognitive Disorders Unit Laboratory, Barcelona.
This laboratory participates in the Alzheimer’s Associ-
ation external quality control programme for CSF
biomarkers [14].
Statistical analysis
We tested the distribution of the values in the sample with
the Kolmogorov-Smirnov test. Differences between groups
were evaluated by Kruskal-Wallis test and Mann-Whitney
test. Spearman correlation coefficients were calculated to
assess the association between NfL and EYO and clinical,
cognitive, and biochemical measures, first across all par-
ticipants and all mutation carriers (MC) and then within
each group. All statistical analyses were performed using
the IBM SPSS (v.20, IBM corp.) software program. Statis-
tical significance was set at p < 0.05.
Results
Twenty-two participants were symptomatic mutation
carriers (SMC) and 38 were asymptomatic, with 20 of
these being mutation carriers (AMC) and 18 being
asymptomatic non-carriers (CTR). AMC were more
than a decade younger than their parental age at onset
(mean ± SD EYO, −14.26 ± 7.68 years; Table 1). As ex-
pected, SMC were significantly older and had lower
scores on cognitive and clinical measures. SMC showed
higher serum NfL levels compared with AMC and CTR
(as well as higher total tau, phosphorylated tau, and NfL,
and lower Aβ1–42 CSF levels). No significant differences
were observed between AMC and CTR in demographic,
clinical, or biochemical variables included in Table 1
except for EYO.
Serum NfL correlations with age, EYO, and clinical,
cognitive, and CSF biochemical measures are shown in
Table 2 and Fig. 1. In MC, serum NfL levels showed a
negative correlation with Mini-Mental State Examin-
ation (MMSE; rho = −0.77, p < 0.001) and positive corre-
lations with EYO and CDR sum of boxes (CDR-SOB)
(rho = 0.75 and 0.70, respectively, both p < 0.001) (Fig.
1a-c and Table 2). When the analysis was restricted to
SMC, serum NfL remained inversely correlated with
MMSE score (rho = −0.48, p = 0.02); when the analysis
was restricted to AMC only, we observed a weaker cor-
relation with EYO (rho = 0.41, p = 0.073 (two-tailed), p
= 0.037 (one-tailed)). Serum NfL levels showed signifi-
cant correlations in MC with several cognitive tests
besides MMSE, such as the Free and Cued Selective
Reminding test sub-scores: total free recall (rho =
−0.54, p = 0.02); total recall (rho = −0.68, p < 0.001);
delayed free recall (rho = −0.57, p = 0,01); delayed total
Sánchez-Valle et al. Alzheimer's Research & Therapy          (2018) 10:113 Page 2 of 6
recall (rho = −0.57, p < 0.001); total Digits score (rho =
−0.57, p < 0.01); Boston naming test (rho = −0.45, p =
0.08); trail making test part A (rho = 0.64, p < 0.001),
and trail making test part B (rho = 0.60, p = 0.002). All
these cognitive measures also showed strong signifi-
cant correlations with MMSE.
Serum NfL correlated with CSF NfL (rho = 0.72, p <
0.001), total tau (rho = 0.71, p < 0.001), and phosphory-
lated tau (rho = 0.71, p < 0.001) (Fig. 1d-f ) but not with
Aβ1–42 levels (rho = −0.32, p = 0.12) in MC. In CTR,
serum NfL correlated with CSF total tau levels, but not
with other markers.
Six available longitudinal serum samples from MC ob-
tained at least 1 year apart were also analysed. The mean
± SD annual longitudinal change was 1.67 ± 1.84 ng/L
(Fig. 2). This value correlated with the baseline EYO
(rho = 0.89, p = 0.019). No longitudinal samples from
CTR were available for comparison.
Table 1 Participant demographics, cognitive test scores, serum and CSF NfL, and CSF Alzheimer’s disease marker concentrations
CTR AMC SMC K-W CTR vs SMC CTR vs AMC SMC vs AMC
M-W U (z; p) M-W U (z; p) M-W U (z; p)
N = 60 (N CSF = 35) 18 (10) 20 (8) 22 (17)
Age (years), mean
(SD)
36.28 (8.51) 34.24 (8.81) 49.16 (10.00) p < 0.001 57 (–3.83; < 0.001) 145 (–1.02; 0.38) 55 (–4.15; < 0.001)
Sex, M/F 7/10 4/17 9/13 na na na na
EYO (years), mean
(SD)
-8.22 (7.9) -14.26 (7.68) 4.12 (2.52) p < 0.001 20 (–8.40; < 0.001) 106 (–2.16; 0.03) 0 (–5.54; < 0.001)
MMSE, mean (SD) 29.17 (1,04) 29.35 (0,93) 19.14 (5.46) p < 0.001 3 (–5.34; < 0.001) 198 (0.58; 0.61) 2.5 (–5.55; < 0.001)
CDR, mean (SD) 0 0 1.27 (0.82) p < 0.001 0 (–5.36; < 0.001) na 0 (–5.36; < 0.001)
CDR-SOB, mean
(SD)
0 0 5.69 (4.15) p < 0.001 0 (–5.39; < 0.001) na 0 (–5.39; < 0.001)
Serum NfL (ng/L),
mean (SD)
13.85 (5.63) 12.43 (6.48) 30.87 (15.14) p < 0.001 39 (–4.32; < 0.001) 142 (–1.11; 0.27) 39 (–4.56; < 0.001)
CSF NfL (ng/L),
mean (SD)
526.53 (198.89) 517.50 (85.02) 2123.19 (649.45) p < 0.001 1 (–3.84; < 0.001) 31 (–0.53; 1) 0 (–3.60; < 0.001)
CSF Aβ1–42 (ng/L),
mean (SD)
753.98 (231.97) 950.52 (542.67) 327.46 (136.71) p < 0.001 3 (–4.12, < 0.001) 49 (0.80; 0.46) 12 (–3.26; < 0.001)
CSF total tau (ng/L),
mean (SD)
233.70 (73.48) 243.23 (52.12) 1166.60 (958.79) p < 0.001 2 (–4.17; < 0.001) 40 (0.00; 1) 0 (–3.96; < 0.001)
CSF p-tau (ng/L),
mean (SD)
44.63 (10.92) 49.25 (11.00) 153.34 (132.26) p < 0.001 9 (–3.82; < 0.001) 50.50 (0.93;0.36) 12 (–3.26; < 0.001)
Significant results are indicated in bold typeface
AMC asymptomatic mutation carriers, CTR non-carriers, CDR Clinical Dementia Rating, CDR-SOB Clinical Dementia Rating sum of boxes, CSF cerebrospinal fluid,
EYO estimated years from symptom onset, K-W Kruskal-Wallis test, M/F male/female, MMSE Mini-Mental State Examination, M-W U Mann-Whitney U test, na not
applicable, NfL neurofilament light, p-tau phosphorylated tau, SD standard deviation, SMC symptomatic mutation carriers
Table 2 Serum NfL level correlations with demographic, clinical, cognitive, and biochemical measures
Whole sample rho(p value) CTRrho(p value) MCrho(p value) AMCrho(p value) SMCrho(p value)
N (N CSF) 60 (35) 18 (10) 42 (25) 20 (8) 22 (17)
Age 0.58 (< 0.001) 0.03 (0.92) 0.64 (< 0.001) 0.35 (0.13) 0.31 (0.16)
EYO 0.65 (< 0.001) −0.25 (0.31) 0.75 (< 0.001) 0.41 (0.07) 0.29 (0.19)
MMSE −0.65 (< 0.001) 0.24 (0.34) −0.77 (< 0.001) −0.30 (0.13) −0.48 (0.02)
CDR-SOB 0.62 (< 0.001) na 0.70 (< 0.001) na 0.35 (0.18)
CSF NfL 0.70 (< 0.001) 0.22 (0.58) 0.72 (< 0.001) 0.66 (0.16) 0.41 (0.17)
CSF Aβ1–42 −0.43 (0.01) 0.04 (0.91) −0.32 (0.12) 0.24 (0.57) 0.33 (0.19)
CSF total tau 0.59 (< 0.001) −0.68 (0.03) 0.71 (< 0.001) 0.19 (0.65) 0.39 (0.12)
CSF p-tau 0.60 (< 0.001) −0,56 (0.09) 0,71 (< 0.001) 0.19 (0.65) 0.41 (0.10)
Significant results are indicated in bold typeface
AMC asymptomatic mutation carriers, CTR non-carriers, CDR-SOB Clinical Dementia Rating sum of boxes, CSF cerebrospinal fluid, EYO estimated years from symptom
onset, MC mutation carriers, MMSE Mini-Mental State Examination, na not applicable, NfL neurofilament light, p-tau phosphorylated tau, SMC symptomatic
mutation carriers
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Discussion
We found that serum NfL concentrations correlated
with severity measures in ADAD mutation carriers, as
well as with CSF NfL, total tau, and phosphorylated tau
levels. Serum NfL levels in MC correlated with the esti-
mated years to symptom onset (EYO). In participants
who were already symptomatic (SMC), NfL levels corre-
lated with global cognition (MMSE). SMC showed in-
creased NfL levels compared with both CTR and AMC
but we did not find a significant difference between the
CTR and the AMC groups who were, as a group,
14 years younger than the parental age of onset. In a
previous study, Weston and colleagues studied serum
NfL with the same methodology in 48 individuals from a
different ADAD cohort [7]. In this cohort, like ours,
serum NfL correlated with EYO and cognitive measures
across MC. Different studies suggest that NfL is a
non-specific marker of neurodegeneration [15]. Serum
NfL levels are elevated and may reflect disease intensity,
not only in sporadic AD [6] but also in amyotrophic lat-
eral sclerosis [16], frontotemporal lobar degeneration
[8], Huntington’s disease [10], and Creutzfeldt-Jakob dis-
ease [17]. However, more longitudinal data are needed
to evaluate the reliability of serum NfL in monitoring
the progression of neurodegeneration. Promisingly,
serum NfL levels are normalized in response to disease-
modifying therapies in multiple sclerosis [18].
NfL may also be useful for predicting symptom onset
in genetic neurodegenerative conditions such as fronto-
temporal dementia [19], genetic Creutzfeldt-Jakob dis-
ease [17], or genetic amyotrophic lateral sclerosis [20],
although it is still unclear when increased levels can first
be detected in these different disorders and whether NfL
rises in the asymptomatic phase of each disease or only
with symptom onset.
Even if the mean concentrations were similar in the
two studies (CTR 12.7 ± 7.2 pg/mL; AMC 16.7 ± 7.7 pg/
mL, and SMC 46.0 ± 20.8 pg/mL), Weston and col-
leagues reported significantly increased serum NfL in
Fig. 1 Correlations of serum neurofilament light (NfL) levels with relevant variables in mutation carriers. a Estimated years to/from symptom
onset (EYO), b Mini-Mental State Examination (MMSE), c Clinical Dementia Rating sum of boxes (CDR-SOB), d cerebrospinal fluid (CSF) NfL, e CSF
total tau (T-tau), and f CSF phosphorylated tau (Ptau)
Fig. 2 Individual paired (basal + longitudinal) serum neurofilament
light (NfL) levels. EYO estimated years to/from symptom onset. MC
mutation carriers
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AMC compared with CTR in ADAD; that differed from
our results. Differences in the mean EYO in AMC could
account for this discrepancy, as serum NfL correlated
with EYO in both cohorts and the asymptomatic carriers
were closer to symptom onset in the UCL cohort than
in our study. Similarly, although they should be consid-
ered exploratory results due to the limited sample size
and the absence of controls, in our study the serum NfL
levels increased longitudinally with the rate of change in
SMC higher than in the AMC, suggesting that the mag-
nitude of annual NfL change might increase with disease
progression. Thus, these results would support the idea
of a progressive increase in serum NfL and, thus, neuro-
degeneration during the asymptomatic phase of the dis-
ease that might accelerate around the time of symptom
onset. No individuals in the severe phases of the disease
were included in any of the studies to evaluate if the in-
crease in serum NfL is maintained in advanced phases of
the disease.
Serum NfL levels significantly correlated with CSF NfL
levels in the whole cohort and across MC as described
in other studies in different neurodegenerative diseases
[6, 15, 19]. Serum NfL also correlated with CSF total tau
and phosphorylated tau levels, although these correla-
tions were not statistically significant within diagnostic
groups, suggesting that the pathological condition
reflected by each biomarker may diverge in different
stages of the AD continuum, as has been shown in spor-
adic AD [6]. However, we cannot rule out a type II error
(false negative result) in our study due to the small sam-
ple size when AMC and SMC were analysed separately.
There are several limitations in this study. Although
the sample size is relatively large for the rarity of ADAD,
the sample size limited the interpretation of some of the
analyses and it would be of interest to explore these re-
sults in larger cohorts. It would be of great interest to
know if different mutations have a different effect on
serum NfL levels, but unfortunately the low numbers of
subjects from each mutation preclude this analysis. The
lack of repeated individual samples in most of the partic-
ipants also limits the interpretation of the reliability of
the marker at the individual level in longitudinal studies.
Conclusions
In summary, serum NFL levels in ADAD MC are associ-
ated with expected time to symptom onset, with clinical
and cognitive measures, and with CSF neurodegenera-
tion markers. These findings suggest that serum NfL
may be a non-invasive biomarker for the prediction of
symptom onset and potentially for tracking disease
severity in ADAD.
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